Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
7
DOCS Quote, Financials, Valuation and Earnings
Last price:
$27.73
Seasonality move
:
-11.03%
Day range:
$23.66 - $27.89
52-week range:
$23.66 - $85.21
Dividend yield:
0%
P/E ratio:
23.28x
P/S ratio:
8.74x
P/B ratio:
5.23x
Volume:
23.1M
Avg. volume:
3.6M
1-year change:
-52.4%
Market cap:
$5.1B
Revenue:
$570.4M
EPS (TTM):
$1.19
Analysts' Opinion
-
Consensus RatingDoximity, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.90, Doximity, Inc. has an estimated upside of 69.15% from its current price of $27.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 9.85% downside risk from its current price of $27.73.
Fair Value
-
According to the consensus of 16 analysts, Doximity, Inc. has 69.15% upside to fair value with a price target of $46.90 per share.
DOCS vs. S&P 500
-
Over the past 5 trading days, Doximity, Inc. has underperformed the S&P 500 by -25.92% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Doximity, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Doximity, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Doximity, Inc. reported revenues of $185.1M.
Earnings Growth
-
Doximity, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Doximity, Inc. reported earnings per share of $0.31.
Enterprise value:
4.4B
EV / Invested capital:
4.44x
Price / LTM sales:
8.74x
EV / EBIT:
17.93x
EV / Revenue:
6.90x
PEG ratio (5yr expected):
1.23x
EV / Free cash flow:
14.31x
Price / Operating cash flow:
18.15x
Enterprise value / EBITDA:
17.02x
Gross Profit (TTM):
$572.4M
Return On Assets:
19.74%
Net Income Margin (TTM):
37.54%
Return On Equity:
22.96%
Return On Invested Capital:
22.7%
Operating Margin:
39.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $468.3M | $550.2M | $637.8M | $168.6M | $185.1M | |
| Gross Profit | $416.6M | $496.2M | $572.4M | $154.4M | $166.4M | |
| Operating Income | $164M | $224M | $245.3M | $80M | $73.9M | |
| EBITDA | $176M | $234.4M | $258.4M | $82.7M | $77.9M | |
| Diluted EPS | $0.66 | $1.00 | $1.19 | $0.37 | $0.31 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $853.3M | $892.9M | $835M | $1B | $984.6M | |
| Total Assets | $932.2M | $1.1B | $1B | $1.2B | $1.2B | |
| Current Liabilities | $91.7M | $105.9M | $104.8M | $115.9M | $149.8M | |
| Total Liabilities | $93.3M | $136.9M | $136M | $141M | $177.7M | |
| Total Equity | $838.8M | $930.2M | $864.6M | $1B | $979.3M | |
| Total Debt | $668K | $14.2M | $12.9M | $10.7M | $8.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $166.8M | $238.7M | $315.4M | $65.2M | $60.9M | |
| Cash From Investing | $94.2M | -$81M | -$15.3M | -$58.9M | $38.2M | |
| Cash From Financing | -$274.3M | -$115.5M | -$400.6M | -$25.2M | -$203.5M | |
| Free Cash Flow | $161.6M | $232.1M | $307.2M | $63.4M | $58.5M | |
DOCS
Sector
Market Cap
$5.1B
$23.4M
Price % of 52-Week High
32.54%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
4.29%
-1.67%
1-Year Price Total Return
-52.4%
-23.18%
Beta (5-Year)
--
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$35.41
200-day SMA
Sell
Level
$57.14
Bollinger Bands (100)
Sell
Level
40.97 - 67.09
Chaikin Money Flow
Buy
Level
11.7M
20-day SMA
Sell
Level
$38.83
Relative Strength Index (RSI14)
Sell
Level
13.53
ADX Line
Sell
Level
51.65
Williams %R
Neutral
Level
-77.9643
50-day SMA
Sell
Level
$43.15
MACD (12, 26)
Sell
Level
-3.22
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-41.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (36.9068)
Buy
CA Score
(Annual)
Level (2.1743)
Buy
Beneish M-Score
(Annual)
Level (-2.4392)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-5.8662)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, DOCS has received 10 Buy ratings 6 Hold ratings, and 0 Sell ratings. The DOCS average analyst price target in the past 3 months is $46.90.
-
Where Will Doximity, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Doximity, Inc. share price will rise to $46.90 per share over the next 12 months.
-
What Do Analysts Say About Doximity, Inc.?
Analysts are divided on their view about Doximity, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Doximity, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Doximity, Inc.'s Price Target?
The price target for Doximity, Inc. over the next 1-year time period is forecast to be $46.90 according to 16 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is DOCS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Doximity, Inc. is a Buy. 10 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DOCS?
You can purchase shares of Doximity, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Doximity, Inc. shares.
-
What Is The Doximity, Inc. Share Price Today?
Doximity, Inc. was last trading at $27.73 per share. This represents the most recent stock quote for Doximity, Inc.. Yesterday, Doximity, Inc. closed at $27.73 per share.
-
How To Buy Doximity, Inc. Stock Online?
In order to purchase Doximity, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DOCS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DOCS
Sector
P/E ratio
23.28x
23.40x
PEG ratio
1.23x
-0.01x
P/B ratio
5.23x
1.74x
Price / LTM sales
8.74x
1.48x
Growth Metrics
DOCS
Sector
Revenue growth
9.76%
3.36%
Earnings growth
-16.89%
9.35%
Revenue (5-year growth)
37.42%
6.22%
Earnings forecast
$0.45
-$0.19
Profitability
DOCS
Sector
Profitability FY 2024
$514.5M
$2.7M
Return on invested capital
22.7%
-33.62%
Return on assets
19.74%
-29.68%
Return on equity
22.96%
-38.98%
Earnings Date
Last Earnings Date
Feb
5
Next Earnings Date
May
14
Estimated Next Earnings Date
May
7
Balance Sheet
DOCS
Sector
Total cash
$735.1M
$25M
Short term investments
$706.1M
$23.9M
Total assets
$1.3B
$72.5M
Long term debt
$8.6M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
